Global Vinorelbine Tartrate Market is expected to grow at a CAGR of XX% during the forecast period. The growth of this market can be attributed to the increasing number of cancer cases and rise in awareness about cancer. The global vinorelbine tartrate market is segmented on the basis of type, application, and region. Oral vinorelbine tartrate is expected to dominate the global vinorelbine tartrate market during the forecast period due to its easy administration route. Breast cancer application segment is expected to dominate the global vinorelbine tartrate market during the forecast period due to its high incidence rate in women population. North America region dominates this market followed by Europe, Asia Pacific, Latin America and Middle East & Africa regions respectively.
- The drug is used to treat breast cancer in women who have been diagnosed with metastatic disease.
- It is also used to treat advanced prostate cancer in men who have not responded to other treatments, such as hormone therapy or chemotherapy.
- Vinorelbine Tartrate has been approved for use in the United States since 1985 and has been available on the market since 1986.
- The drug is marketed by Sanofi-Aventis under the trade name Navelbine and was originally developed by Rhone-Poulenc Rorer Pharmaceuticals, Inc, a subsidiary of Sanofi-Aventis US, Inc, which was acquired by Sanofi-Aventis in 2001.
- Vinorelbine Tartrate is a semi-synthetic derivative of vinblastine.
Industry Growth Insights published a new data on “Vinorelbine Tartrate Market”. The research report is titled “Vinorelbine Tartrate Market research by Types (Oral, Injection), By Applications (Breast Cancer, Lymphoma, Non-small Cell Lung Cancer, Others), By Players/Companies TEVA Pharms, Novartis, Pierre Fabre, Hospira, Hikma, Fresenius Kabi, Hansoh Pharma, Mylan, Dr. Reddy's Laboratories, Hangzhou Minsheng Pharmaceutical Group, Nanjing Cuccess Pharmaceutical, Qilu Pharmaceutical, Sinopharm Group, Beijing SL Pharm, Shenzhen Main Luck Pharmaceuticals, Harbin Gloria, Luoxin Group”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vinorelbine Tartrate Market Research Report
By Type
Oral, Injection
By Application
Breast Cancer, Lymphoma, Non-small Cell Lung Cancer, Others
By Companies
TEVA Pharms, Novartis, Pierre Fabre, Hospira, Hikma, Fresenius Kabi, Hansoh Pharma, Mylan, Dr. Reddy's Laboratories, Hangzhou Minsheng Pharmaceutical Group, Nanjing Cuccess Pharmaceutical, Qilu Pharmaceutical, Sinopharm Group, Beijing SL Pharm, Shenzhen Main Luck Pharmaceuticals, Harbin Gloria, Luoxin Group
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Vinorelbine Tartrate Market Report Segments:
The global Vinorelbine Tartrate market is segmented on the basis of:
Types
Oral, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Breast Cancer, Lymphoma, Non-small Cell Lung Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- TEVA Pharms
- Novartis
- Pierre Fabre
- Hospira
- Hikma
- Fresenius Kabi
- Hansoh Pharma
- Mylan
- Dr. Reddy's Laboratories
- Hangzhou Minsheng Pharmaceutical Group
- Nanjing Cuccess Pharmaceutical
- Qilu Pharmaceutical
- Sinopharm Group
- Beijing SL Pharm
- Shenzhen Main Luck Pharmaceuticals
- Harbin Gloria
- Luoxin Group
Highlights of The Vinorelbine Tartrate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Injection
- By Application:
- Breast Cancer
- Lymphoma
- Non-small Cell Lung Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vinorelbine Tartrate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Vinorelbine tartrate is a chemotherapy drug used to treat cancer. It works by stopping the growth of cancer cells. Vinorelbine tartrate is usually given as an injection into a vein.
Some of the major companies in the vinorelbine tartrate market are TEVA Pharms, Novartis, Pierre Fabre, Hospira, Hikma, Fresenius Kabi, Hansoh Pharma, Mylan, Dr. Reddy's Laboratories, Hangzhou Minsheng Pharmaceutical Group, Nanjing Cuccess Pharmaceutical, Qilu Pharmaceutical, Sinopharm Group, Beijing SL Pharm, Shenzhen Main Luck Pharmaceuticals, Harbin Gloria, Luoxin Group.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vinorelbine Tartrate Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vinorelbine Tartrate Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vinorelbine Tartrate Market - Supply Chain
4.5. Global Vinorelbine Tartrate Market Forecast
4.5.1. Vinorelbine Tartrate Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vinorelbine Tartrate Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vinorelbine Tartrate Market Absolute $ Opportunity
5. Global Vinorelbine Tartrate Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vinorelbine Tartrate Market Size and Volume Forecast by Type
5.3.1. Oral
5.3.2. Injection
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vinorelbine Tartrate Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vinorelbine Tartrate Market Size and Volume Forecast by Application
6.3.1. Breast Cancer
6.3.2. Lymphoma
6.3.3. Non-small Cell Lung Cancer
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vinorelbine Tartrate Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vinorelbine Tartrate Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vinorelbine Tartrate Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vinorelbine Tartrate Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vinorelbine Tartrate Demand Share Forecast, 2019-2026
9. North America Vinorelbine Tartrate Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vinorelbine Tartrate Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vinorelbine Tartrate Market Size and Volume Forecast by Application
9.4.1. Breast Cancer
9.4.2. Lymphoma
9.4.3. Non-small Cell Lung Cancer
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vinorelbine Tartrate Market Size and Volume Forecast by Type
9.7.1. Oral
9.7.2. Injection
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vinorelbine Tartrate Demand Share Forecast, 2019-2026
10. Latin America Vinorelbine Tartrate Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vinorelbine Tartrate Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vinorelbine Tartrate Market Size and Volume Forecast by Application
10.4.1. Breast Cancer
10.4.2. Lymphoma
10.4.3. Non-small Cell Lung Cancer
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vinorelbine Tartrate Market Size and Volume Forecast by Type
10.7.1. Oral
10.7.2. Injection
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vinorelbine Tartrate Demand Share Forecast, 2019-2026
11. Europe Vinorelbine Tartrate Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vinorelbine Tartrate Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vinorelbine Tartrate Market Size and Volume Forecast by Application
11.4.1. Breast Cancer
11.4.2. Lymphoma
11.4.3. Non-small Cell Lung Cancer
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vinorelbine Tartrate Market Size and Volume Forecast by Type
11.7.1. Oral
11.7.2. Injection
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vinorelbine Tartrate Demand Share, 2019-2026
12. Asia Pacific Vinorelbine Tartrate Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vinorelbine Tartrate Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vinorelbine Tartrate Market Size and Volume Forecast by Application
12.4.1. Breast Cancer
12.4.2. Lymphoma
12.4.3. Non-small Cell Lung Cancer
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vinorelbine Tartrate Market Size and Volume Forecast by Type
12.7.1. Oral
12.7.2. Injection
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vinorelbine Tartrate Demand Share, 2019-2026
13. Middle East & Africa Vinorelbine Tartrate Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vinorelbine Tartrate Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vinorelbine Tartrate Market Size and Volume Forecast by Application
13.4.1. Breast Cancer
13.4.2. Lymphoma
13.4.3. Non-small Cell Lung Cancer
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vinorelbine Tartrate Market Size and Volume Forecast by Type
13.7.1. Oral
13.7.2. Injection
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vinorelbine Tartrate Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Vinorelbine Tartrate Market: Market Share Analysis
14.2. Vinorelbine Tartrate Distributors and Customers
14.3. Vinorelbine Tartrate Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. TEVA Pharms
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pierre Fabre
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Hospira
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Hikma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Fresenius Kabi
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Hansoh Pharma
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Dr. Reddy's Laboratories
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Hangzhou Minsheng Pharmaceutical Group
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Nanjing Cuccess Pharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Qilu Pharmaceutical
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sinopharm Group
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Beijing SL Pharm
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Shenzhen Main Luck Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Harbin Gloria
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Luoxin Group
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
